Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VL-PX10 + VL-P22 for COVID-19 Induced Pulmonary Fibrosis
NCT05387239Phase 2Suspended
- Sponsor
- Vitti Labs
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of VL-PX10, VL-P22 in pulmonary fibrosis (PF), sponsored by Vitti Labs. Started Nov 2022; status: suspended.
02
Drugs
VL-PX10VL-P22
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05387239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387239.